Literature DB >> 2006281

Ischemic brain damage: reduction by sodium-calcium ion channel modulator RS-87476.

J Kucharczyk1, J Mintorovitch, M E Moseley, H S Asgari, R J Sevick, N Derugin, D Norman.   

Abstract

A novel sodium-calcium ion channel modulator, RS-87476, reduced cerebral infarct size in cats subjected to permanent unilateral occlusion of the middle cerebral artery. Cerebral injury was assessed in vivo with a combination of magnetic resonance (MR) imaging and spectroscopy for 5-12 hours after occlusion and was compared with the area of histochemically ischemic brain tissue. Compared with infarcts in placebo-treated animals, infarcts in cats given RS-87476 were reduced by an average of 70% at the lowest dose, 75% at the intermediate dose, and 88% at the highest dose. Tissue edema, observed as areas of signal hyperintensity on diffusion- and T2-weighted spin-echo images, was confined to small regions of the parietal cortex and basal ganglia in drug-treated animals. Mean plasma levels of RS-87476 at the lowest dose were 13 ng/mL initially, falling to maintenance levels of 3-5 ng/mL; at the intermediate and highest doses, plasma levels of drug were approximately five- and 20-fold greater. The drug was only slightly hypotensive. At least part of the potent cerebroprotective effects of RS-87476 result from its ability to stabilize metabolic energy reserves, reduce lactate formation in ischemic tissues, and attenuate intracerebral edema.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2006281     DOI: 10.1148/radiology.179.1.2006281

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  13 in total

1.  Neuroprotective efficacy of lifarizine (RS-87476) in a simplified rat survival model of 2 vessel occlusion.

Authors:  D E McBean; V Winters; A D Wilson; C B Oswald; B J Alps; J M Armstrong
Journal:  Br J Pharmacol       Date:  1995-12       Impact factor: 8.739

2.  Actions of the novel neuroprotective agent, lifarizine (RS-87476), on voltage-dependent sodium currents in the neuroblastoma cell line, N1E-115.

Authors:  J G McGivern; L Patmore; R D Sheridan
Journal:  Br J Pharmacol       Date:  1995-04       Impact factor: 8.739

Review 3.  Drugs acting on calcium channels: potential treatment for ischaemic stroke.

Authors:  B J Alps
Journal:  Br J Clin Pharmacol       Date:  1992-09       Impact factor: 4.335

4.  The effect of lifarizine (RS-87476), a novel sodium and calcium channel modulator, on ischaemic dopamine depletion in the corpus striatum of the gerbil.

Authors:  C M Brown; C Calder; B J Alps; M Spedding
Journal:  Br J Pharmacol       Date:  1993-05       Impact factor: 8.739

5.  Hypoxic and ischemic hypoxia exacerbate brain injury associated with metabolic encephalopathy in laboratory animals.

Authors:  Z S Vexler; J C Ayus; T P Roberts; C L Fraser; J Kucharczyk; A I Arieff
Journal:  J Clin Invest       Date:  1994-01       Impact factor: 14.808

6.  [3H]-lifarizine, a high affinity probe for inactivated sodium channels.

Authors:  A C MacKinnon; K M Wyatt; J G McGivern; R D Sheridan; C M Brown
Journal:  Br J Pharmacol       Date:  1995-07       Impact factor: 8.739

7.  Block of human voltage-sensitive Na+ currents in differentiated SH-SY5Y cells by lifarizine.

Authors:  N A Brown; J A Kemp; G R Seabrook
Journal:  Br J Pharmacol       Date:  1994-10       Impact factor: 8.739

8.  Neuroprotective profile of lifarizine (RS-87476) in rat cerebrocortical neurones in culture.

Authors:  G R May; W S Rowand; J G McCormack; R D Sheridan
Journal:  Br J Pharmacol       Date:  1995-04       Impact factor: 8.739

9.  Reduction by lifarizine of the neuronal damage induced by cerebral ischaemia in rodents.

Authors:  B J Alps; C Calder; A D Wilson; D E McBean; J M Armstrong
Journal:  Br J Pharmacol       Date:  1995-08       Impact factor: 8.739

10.  Neuroprotective properties of lifarizine compared with those of other agents in a mouse model of focal cerebral ischaemia.

Authors:  C M Brown; C Calder; C Linton; C Small; B A Kenny; M Spedding; L Patmore
Journal:  Br J Pharmacol       Date:  1995-08       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.